[HTML][HTML] Attenuation of inflammatory bowel disease by oral administration of mucoadhesive polydopamine-coated yeast β-glucan via ROS scavenging and gut …
F Yang, Y Su, C Yan, T Chen, PCK Cheung - Journal of …, 2024 - Springer
Abstract Treatment for inflammatory bowel disease (IBD) is challenging since current anti-
inflammatory and immunosuppressive therapies do not address the underlying causes of …
inflammatory and immunosuppressive therapies do not address the underlying causes of …
Attenuation of inflammatory bowel disease by oral administration of mucoadhesive polydopamine-coated yeast β-glucan via ROS scavenging and gut microbiota …
F Yang, Y Su, C Yan, T Chen… - Journal of …, 2024 - europepmc.org
Abstract Treatment for inflammatory bowel disease (IBD) is challenging since current anti-
inflammatory and immunosuppressive therapies do not address the underlying causes of …
inflammatory and immunosuppressive therapies do not address the underlying causes of …
Attenuation of inflammatory bowel disease by oral administration of mucoadhesive polydopamine-coated yeast β-glucan via ROS scavenging and gut microbiota …
F Yang, Y Su, C Yan, T Chen… - Journal of …, 2024 - pubmed.ncbi.nlm.nih.gov
Treatment for inflammatory bowel disease (IBD) is challenging since current anti-
inflammatory and immunosuppressive therapies do not address the underlying causes of …
inflammatory and immunosuppressive therapies do not address the underlying causes of …
[HTML][HTML] Attenuation of inflammatory bowel disease by oral administration of mucoadhesive polydopamine-coated yeast β-glucan via ROS scavenging and gut …
F Yang, Y Su, C Yan, T Chen… - Journal of …, 2024 - jnanobiotechnology.biomedcentral …
Treatment for inflammatory bowel disease (IBD) is challenging since current anti-
inflammatory and immunosuppressive therapies do not address the underlying causes of …
inflammatory and immunosuppressive therapies do not address the underlying causes of …
[HTML][HTML] Attenuation of inflammatory bowel disease by oral administration of mucoadhesive polydopamine-coated yeast β-glucan via ROS scavenging and gut …
F Yang, Y Su, C Yan, T Chen… - Journal of …, 2024 - ncbi.nlm.nih.gov
Abstract Treatment for inflammatory bowel disease (IBD) is challenging since current anti-
inflammatory and immunosuppressive therapies do not address the underlying causes of …
inflammatory and immunosuppressive therapies do not address the underlying causes of …
Attenuation of inflammatory bowel disease by oral administration of mucoadhesive polydopamine-coated yeast β-glucan via ROS scavenging and gut microbiota …
F Yang, Y Su, C Yan, T Chen… - Journal of …, 2024 - europepmc.org
Treatment for inflammatory bowel disease (IBD) is challenging since current anti-
inflammatory and immunosuppressive therapies do not address the underlying causes of …
inflammatory and immunosuppressive therapies do not address the underlying causes of …
[PDF][PDF] Attenuation of inflammatory bowel disease by oral administration of mucoadhesive polydopamine-coated yeast β-glucan via ROS scavenging and gut …
F Yang, Y Su, C Yan, T Chen, PCK Cheung - 2024 - jnanobiotechnology.biomedcentral …
Abstract Treatment for inflammatory bowel disease (IBD) is challenging since current anti-
inflammatory and immunosuppressive therapies do not address the underlying causes of …
inflammatory and immunosuppressive therapies do not address the underlying causes of …